ClinicalTrials.gg
Not yet recruitingNCT07843420Updated Sep 28, 2026

Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

A Phase 2 interventional study of Nemolizumab-ilto in Chronic Hepatic Pruritus, Cholestatic Liver Disease and Primary Biliary Cholangitis, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 17 under way, 7 of them phase 3. Liver Cirrhosis, Biliary · United States.

Planned enrollment
55th of 65
15 · median 46
Started
2026
with 5 others
Phase 2
34 of 83
2 open now
Primary completion
2028-11
later than 6 of 16 live
Registered
82nd of 83
by date
Lead sponsor
6 of 83
Mayo Clinic

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 55th largest by planned enrollment of the 65 interventional ones that give a count, is one of 6 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 6 of the 16 other live ones, and was the 82nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.

03

Conditions studied

  • Chronic Hepatic Pruritus
  • Cholestatic Liver Disease
  • Primary Biliary Cholangitis
  • Cholestasis
  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cholestatic pruritus secondary primary biliary sclerosis (PBS) or primary sclerosing cholangitis (PSC)
  • Pruritus that is chronic in duration (greater equal to 6 months)
  • Pruritus severity with a peak pruritus numerical rating score of ≥ 5 (moderate severity)
  • Model for End-Stage Liver Disease (MELD) score \< 15. This will capture patients with chronic stable liver disease without significant comorbid conditions and/or signs of rapidly progressive or decompensated liver failure
  • Willingness and ability to comply with scheduled clinic visits, physical exams, laboratory tests, questionnaires, effective use, and other trial procedures

Exclusion criteria

Exclusion Criteria:

  • Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin to exclude as needed
  • Pregnant females. Urine pregnancy test required at screening
  • History of intrahepatic cholestasis of pregnancy
  • Any form of chronic hepatic pruritus associated with underlying
  • Liver transplant recipients
  • Drug-induced liver pruritus
  • or AST greater than 3 times the or total greater than 2 times upper normal limit
  • Advanced liver disease indicators including, ascites requiring therapeutic paracentesis, history of spontaneous bacterial peritonitis, any grade of hepatic encephalopathy, or a documented history of variceal bleeding within the preceding six months
  • Severe coagulopathy with > 15
  • Any form of acute cholestatic liver disease
  • Allergy to nemolizumab or its ingredients
  • Inability to provide
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Nemolizumab-ilto

    Participants will receive open-label nemolizumab-ilto by subcutaneous injection.

    Drug: Nemolizumab-ilto

Interventions

  • DrugNemolizumabStudies of NemolizumabNemolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive nemolizumab-ilto 60 mg subcutaneously at Week 0, followed by 30 mg subcutaneously every 4 weeks during the treatment period (total of 16 weeks).

    Also known as: NEMLUVIO

06

What researchers measure

Primary outcomes

  1. Mean percent change in the Peak Pruritus Numerical Rating Score (PNRS)

    Pruritus severity is measured using the peak PNRS, a single self-administered item that captures the intensity of the worst itch experienced during the previous 24 hours. Patients respond to the question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" Patients will record daily itch scores in a diary, which will be collected at follow-up visits. The baseline and Week 16 mean peak PNRS values will be calculated as the average of the daily scores recorded over the 7 days immediately preceding treatment initiation and 7 days preceding Week 16 follow up, respectively.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of patients with an improvement in weekly average PNRS ≥4 from baseline

    The proportion of participants with an improvement of at least 4 points from baseline in weekly average Peak Pruritus Numerical Rating Score will be assessed at each specified post-baseline time point.

    Time frame: Weeks 1,2,4,8, and 12

  2. Change in Verbal Rating Scale of Pruritus

    The Verbal Rating Scale of pruritus is assessed using a 4-point scale where 0 indicates none, 1 indicates mild, 2 indicates moderate, and 3 indicates severe or intense pruritus. Change from baseline will be summarized at each specified post-baseline time point.

    Time frame: Weeks 1,2,4,8, and 12

  3. Mean change of 5D pruritus score

    This is a multidimensional questionnaire designed to assess the degree, duration, direction, disability and distribution of pruritus longitudinally with scoring ranging from 5=no pruritus/well-controlled to 25=severe pruritus/poorly controlled.

    Time frame: Baseline, Week 12

  4. Change in Chronic Liver Disease Questionnaire (CLDQ) score

    This is a validated quality life instrument for patients with chronic liver disease evaluating systemic symptoms, fatigue, physical activity, emotional function, and worry using a 7 point scale with 1=all of the time; 2=most of the time; 3=a good bit of the time; 4=some of the time; 5=a little of the time; 6=hardly any of the time; and 7=none of the time.

    Time frame: Baseline, Week 12

  5. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Item Bank mean score

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Item Banks assess a wide spectrum of self-reported fatigue symptoms, ranging from mild feelings of tiredness to overwhelming, debilitating, and sustained exhaustion that can significantly impair an individual's ability to perform daily activities and fulfill family or social roles. Each item is rated on a 5-point Likert scale, and the resulting raw scores are converted into T-scores, which are then compared to a standardized mean (T-score mean = 50, SD = 10).

    Time frame: Baseline, Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843420
Lead sponsor
Mayo Clinic
Responsible party
Jason Sluzevich MD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Reagan E. Dukes, MHA
Contact
dukes.reagan@mayo.edu
904-953-3302
Jason Sluzevich, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion